

SENATE APPROPRIATIONS COMMITTEE FISCAL NOTE

BILL NO. Senate Bill 683

PRINTER NO. 929

AMOUNT

No Fiscal Impact

FUND

General Fund

DATE INTRODUCED

May 15, 2023

PRIME SPONSOR

Senator Mastriano

DESCRIPTION

Senate Bill 683 amends Title 35 (Health and Safety) to require urine drug screening for fentanyl and xylazine, if a urine drug screening is conducted in a general acute care hospital to assist in diagnosing a patient's condition.

Senate Bill 683 stipulates that if the urine drug screening detects fentanyl or xylazine, the hospital shall deidentify the test results and report them to the Department of Health through PA-NEDSS, which is Pennsylvania's National Electronic Disease Surveillance System. Nothing in this legislation shall preclude an acute care hospital without analyzer equipment for urinalysis from utilizing fentanyl test strips or xylazine test strips.

This act shall take in 60 days.

FISCAL IMPACT:

Senate Bill 683 will have a no fiscal impact to the Commonwealth.